Literature DB >> 1139485

Multiple fluoroscopy of the chest: carcinogenicity for the female breast and implications for breast cancer screening programs.

N C Delarue, G Gale, A Ronald.   

Abstract

The risk of radiation carcinogenesis has been established for breast tissue from experience with total body irradiation and multiple fluoroscopy of the chest with the patient prone. The doubling dose has been estimated to lie between 20 and 50 rads. Before undertaking radiologic screening programs for breast cancer, therefore, it is necessary to determine whether exposures below this range are safe. Of 792 women who had had tuberculosis and were followed for a minimum of 20 years, 451 had had multiple fluoroscopy while supine; 341 had not had fluoroscopy. The first group received a total radiation dose to the breast averaging 17 rads (141.5 fluoroscopies); the incidence of breast cancer in this group was not increased. Had fluoroscopy been performed with the patient prone the total radiation dose would have averaged 308 rads. The difference is thought to explain the increased incidence of breast cancer attributable to fluoroscopy given with the patient prone. Mid-breast exposure with mammography or xeroradiography varies between 3 and 6 rads. Repetitive screening would, therefore, appear safe provided total exposure did not exceed 20 rads. With this restriction there would appear to be no reason to curtail screening of women for breast cancer.

Entities:  

Mesh:

Year:  1975        PMID: 1139485      PMCID: PMC1956229     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  8 in total

1.  Mammography and cancer of the breast.

Authors:  D McFarlane
Journal:  Can Med Assoc J       Date:  1972-04-08       Impact factor: 8.262

2.  Lung cancer following atomic radiation.

Authors:  C K Wanebo; K G Johnson; K Sato; T W Thorslund
Journal:  Am Rev Respir Dis       Date:  1968-11

3.  Breast cancer after exposure to the atomic bombings of Hiroshima and Nagasaki.

Authors:  C K Wanebo; K G Johnson; K Sato; T W Thorslund
Journal:  N Engl J Med       Date:  1968-09-26       Impact factor: 91.245

4.  Radiation-induced breast cancer.

Authors:  A R Tamplin; J W Gofman
Journal:  Lancet       Date:  1970-02-07       Impact factor: 79.321

5.  Breast cancer following multiple fluoroscopies during artificial pneumothorax treatment of pulmonary tuberculosis.

Authors:  J A Myrden; J E Hiltz
Journal:  Can Med Assoc J       Date:  1969-06-14       Impact factor: 8.262

6.  Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis.

Authors:  W M Brown; R Doll
Journal:  Br Med J       Date:  1965-12-04

7.  Isoniazid therapy in relation to later occurrence of cancer in adults and in infants.

Authors:  E C Hammond; I J Selikoff; E H Robitzek
Journal:  Br Med J       Date:  1967-06-24

8.  BREAST CANCER FOLLOWING MULTIPLE FLUOROSCOPIES.

Authors:  I MACKENZIE
Journal:  Br J Cancer       Date:  1965-03       Impact factor: 7.640

  8 in total
  6 in total

1.  Radiation risks of mammography: another view.

Authors:  L Breslow
Journal:  West J Med       Date:  1976-12

2.  Computed tomographic colonography: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2003-10-01

3.  Computed Tomographic (CT) Colonography for Colorectal Cancer Screening: An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-09-01

4.  Dermatologic radiotherapy and breast cancer. Dose measurements and risk quantification.

Authors:  H Goldschmidt; R O Gorson; M Lassen
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

5.  Early diagnosis of breast cancer: experience in a consultant breast clinic.

Authors:  L J Mahoney; B L Bird; G M Cooke; D G Ball
Journal:  Can Med Assoc J       Date:  1977-05-21       Impact factor: 8.262

6.  Factors that promote the development of human breast cancer.

Authors:  D B Thomas
Journal:  Environ Health Perspect       Date:  1983-04       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.